



A monthly report summarizing life science transactions in Washington State.

BY THE NUMBERS: 86 TRANSACTIONS TOTALING OVER \$4.52B (YTD)



SEPTEMBER TOP TRANSACTIONS

RareCyte has announced the completion of a \$24M financing from new and existing investors. The funding will drive the commercialization and applications for the Company's new Orion spatial biology platform and further global expansion for the Company's portfolio of instruments and consumables ([RareCyte](#)).

Xealth, which handles digital health strategies for more than 20 hospital systems, has raised \$24M in new funding, the Seattle-based startup announced Tuesday. Xealth's platform builds on the growing ecosystem of health care apps and digital services ([GeekWire](#)).

A-Alpha Bio plans to build lab space in downtown Seattle and beef up its machine learning team with \$20M in new venture funding for its operation to identify therapeutic proteins. Seattle's Madrona Venture Group, a tech-focused firm branching into the life sciences, led the Series A round ([GeekWire](#)).

OTHER TRENDS & HIGHLIGHTS

Cyrus Biotechnology is entering a protein engineering collaboration with Boston-based Selecta Biosciences that could pull in up to \$1.5B for the University of Washington spinout. The partnership will support the development of new agents for immune-related conditions ([GeekWire](#)).

Impel NeuroPharma shares were up 20% to \$27.69 after the company said the U.S. Food and Drug Administration approved Trudhesa dihydroergotamine mesylate nasal spray for the acute treatment of migraine with or without aura in adults ([MarketWatch](#)).

Life Science Real Estate remains hot with South Lake Union building selling for near-record price. Alexandria Real Estate Equities has sold a 70% interest in its 400 Dexter life sciences building in the South Lake Union neighborhood for \$254.8M, or \$1,255 per rentable square foot ([Puget Sound Business Journal](#)).

Alpine Immune Sciences announced they have entered into a definitive securities purchase agreement for the sale of common stock and prefunded warrants, in a private placement with certain institutional and other accredited investors for gross proceeds to Alpine of approximately \$91M* ([Alpine Immune Sciences](#)).

TRANSACTIONS

Date	Company	Sector	Type	Amount	Location
08-Sep-2021	A-Alpha Bio	Biotech	Early Stage VC	\$20,290,000	Seattle
09-Sep-2021	RareCyte	Medtech	Later Stage VC	\$24,050,000	Seattle
21-Sep-2021	Xealth	Digital Health	Later Stage VC	\$24,000,000	Seattle
23-Sep-2021	Sync.MD	Digital Health	Later Stage VC	\$10,000,000	Redmond
27-Sep-2021	Tegria	Digital Health	Angel (Individual)	\$6,730,000	Renton
September Total (disclosed transactions):				\$84,970,000	
<u>August Total (disclosed transactions):</u>				<u>\$104,260,000</u>	
<u>July Total (disclosed transactions):</u>				<u>\$660,550,000</u>	
<u>June Total (disclosed transactions):</u>				<u>\$572,110,000</u>	
<u>May Total (disclosed transactions):</u>				<u>\$14,530,000</u>	
<u>April Total (disclosed transactions):</u>				<u>\$841,190,000</u>	
<u>March Total (disclosed transactions):</u>				<u>\$1,089,960,000</u>	
<u>February Total (disclosed transactions):</u>				<u>\$666,580,000</u>	
<u>January Total (disclosed transactions):</u>				<u>\$478,070,000</u>	